The Experts below are selected from a list of 324 Experts worldwide ranked by ideXlab platform

Carl G. Figdor - One of the best experts on this subject based on the ideXlab platform.

  • pMel17 is recognised by monoclonal antibodies NKI-beteb, HMB-45 and HMB-50 and by anti-melanoma CTL.
    British journal of cancer, 1996
    Co-Authors: Gosse J. Adema, Alexander B.h. Bakker, A.j. De Boer, Peter Hohenstein, Carl G. Figdor
    Abstract:

    Recently, we cloned the cDNA encoding the melanocyte lineage-specific antigen gp100 and demonstrated that gp100 is recognised by three different monoclonal antibodies (MAbs) used to diagnose malignant melanoma. In addition, we showed that tumour-infiltrating lymphocytes (TIL 1200) from a melanoma patient reacted specifically with cells transfected with the gp100 cDNA. Molecular characterisation of the gp100 cDNA revealed that the gp100 antigen is highly homologous, but not identical, to another melanocyte-specific protein, pMel17. Here, we report that cells transfected with pMel17 cDNA also react with all three MAbs used to diagnose malignant melanoma, NKI-beteb, HMB-45 and HMB-50. Moreover, pMel17 transfectants are specifically lysed by TIL1200. These data demonstrate that antigenic processing of both gp100 and pMel17 give rise to peptides seen by anti-melanoma cytotoxic T lymphocytes (CTL) and are therefore potential targets for immunotherapy of malignant melanoma.

  • Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA.
    The American journal of pathology, 1993
    Co-Authors: G.j. Adema, A.j. De Boer, R. Van 't Hullenaar, M. Denijn, D.j. Ruiter, A.m. Vogel, Carl G. Figdor
    Abstract:

    The glycoproteins recognized by monoclonal antibody (MAb) NKI-beteb are among the best diagnostic markers for human melanoma. MAb NKI-beteb reacts with melanoma cells throughout tumor development and does not cross-react with other tumor or normal cells, except for cells of the melanocytic lineage. Two other melanocyte lineage-specific MAbs, HMB-50 and HMB-45, show a specificity and staining pattern strikingly similar to the ones observed for NKI-beteb. Herein, we demonstrate that all three MAbs recognize protein products encoded by a single cDNA. Expression of this cDNA in BLM cells results in immunoreactivity with all three MAbs. In addition, we demonstrate co-distribution of the RNA species detected by the cDNA with the proteins recognized by the MAbs in tissue sections.

M. Kaneko - One of the best experts on this subject based on the ideXlab platform.

  • HMB-45 reactivity in renal angiomyolipoma and lymphangioleiomyomatosis.
    Archives of pathology & laboratory medicine, 1994
    Co-Authors: V. Hoon, Swan N. Thung, M. Kaneko, Pamela D. Unger
    Abstract:

    Recent reports have elucidated the variety of tissue types that can react with HMB-45. Consistent positivity has been demonstrated in angiomyolipomas, but only in the smooth-muscle cells. In this report, we examine five renal angiomyolipomas and 20 mesenchymal lesions with similar morphological features and with a possibly similar histogenesis. These include one retroperitoneal lymphangioleiomyomatosis, five epithelioid leiomyomas, nine leiomyosarcomas with epithelioid features, and five alveolar soft part sarcomas. HMB-45 demonstrated a strong diffuse cytoplasmic positive reaction with the smooth-muscle component in all cases of renal angiomyolipoma and in the one case of lymphangioleiomyomatosis. All alveolar soft part sarcomas, leiomyomas, and leiomyosarcomas were uniformly negatively stained by this antibody. We discuss the widening spectrum of lesions that are reactive with HMB-45 and the relationship of angiomyolipoma and lymphangioleiomyomatosis.

  • HMB-45 reactivity in adrenal pheochromocytomas.
    Archives of pathology & laboratory medicine, 1992
    Co-Authors: Pamela D. Unger, Swan N. Thung, K Hoffman, D Pertsemlides, D Wolfe, M. Kaneko
    Abstract:

    Melanoma-specific antibody (HMB-45) is highly specific for junctional nevi, malignant melanomas, and related lesions. Rarely have other benign or neoplastic tissues demonstrated positivity with the monoclonal antibody following purification. In the present study, four of 12 pheochromocytomas contained chief cells that reacted with HMB-45. We discuss the clinical and pathologic implications of this finding.

A.j. De Boer - One of the best experts on this subject based on the ideXlab platform.

  • pMel17 is recognised by monoclonal antibodies NKI-beteb, HMB-45 and HMB-50 and by anti-melanoma CTL.
    British journal of cancer, 1996
    Co-Authors: Gosse J. Adema, Alexander B.h. Bakker, A.j. De Boer, Peter Hohenstein, Carl G. Figdor
    Abstract:

    Recently, we cloned the cDNA encoding the melanocyte lineage-specific antigen gp100 and demonstrated that gp100 is recognised by three different monoclonal antibodies (MAbs) used to diagnose malignant melanoma. In addition, we showed that tumour-infiltrating lymphocytes (TIL 1200) from a melanoma patient reacted specifically with cells transfected with the gp100 cDNA. Molecular characterisation of the gp100 cDNA revealed that the gp100 antigen is highly homologous, but not identical, to another melanocyte-specific protein, pMel17. Here, we report that cells transfected with pMel17 cDNA also react with all three MAbs used to diagnose malignant melanoma, NKI-beteb, HMB-45 and HMB-50. Moreover, pMel17 transfectants are specifically lysed by TIL1200. These data demonstrate that antigenic processing of both gp100 and pMel17 give rise to peptides seen by anti-melanoma cytotoxic T lymphocytes (CTL) and are therefore potential targets for immunotherapy of malignant melanoma.

  • Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA.
    The American journal of pathology, 1993
    Co-Authors: G.j. Adema, A.j. De Boer, R. Van 't Hullenaar, M. Denijn, D.j. Ruiter, A.m. Vogel, Carl G. Figdor
    Abstract:

    The glycoproteins recognized by monoclonal antibody (MAb) NKI-beteb are among the best diagnostic markers for human melanoma. MAb NKI-beteb reacts with melanoma cells throughout tumor development and does not cross-react with other tumor or normal cells, except for cells of the melanocytic lineage. Two other melanocyte lineage-specific MAbs, HMB-50 and HMB-45, show a specificity and staining pattern strikingly similar to the ones observed for NKI-beteb. Herein, we demonstrate that all three MAbs recognize protein products encoded by a single cDNA. Expression of this cDNA in BLM cells results in immunoreactivity with all three MAbs. In addition, we demonstrate co-distribution of the RNA species detected by the cDNA with the proteins recognized by the MAbs in tissue sections.

Pamela D. Unger - One of the best experts on this subject based on the ideXlab platform.

  • HMB-45 reactivity in renal angiomyolipoma and lymphangioleiomyomatosis.
    Archives of pathology & laboratory medicine, 1994
    Co-Authors: V. Hoon, Swan N. Thung, M. Kaneko, Pamela D. Unger
    Abstract:

    Recent reports have elucidated the variety of tissue types that can react with HMB-45. Consistent positivity has been demonstrated in angiomyolipomas, but only in the smooth-muscle cells. In this report, we examine five renal angiomyolipomas and 20 mesenchymal lesions with similar morphological features and with a possibly similar histogenesis. These include one retroperitoneal lymphangioleiomyomatosis, five epithelioid leiomyomas, nine leiomyosarcomas with epithelioid features, and five alveolar soft part sarcomas. HMB-45 demonstrated a strong diffuse cytoplasmic positive reaction with the smooth-muscle component in all cases of renal angiomyolipoma and in the one case of lymphangioleiomyomatosis. All alveolar soft part sarcomas, leiomyomas, and leiomyosarcomas were uniformly negatively stained by this antibody. We discuss the widening spectrum of lesions that are reactive with HMB-45 and the relationship of angiomyolipoma and lymphangioleiomyomatosis.

  • HMB-45 reactivity in adrenal pheochromocytomas.
    Archives of pathology & laboratory medicine, 1992
    Co-Authors: Pamela D. Unger, Swan N. Thung, K Hoffman, D Pertsemlides, D Wolfe, M. Kaneko
    Abstract:

    Melanoma-specific antibody (HMB-45) is highly specific for junctional nevi, malignant melanomas, and related lesions. Rarely have other benign or neoplastic tissues demonstrated positivity with the monoclonal antibody following purification. In the present study, four of 12 pheochromocytomas contained chief cells that reacted with HMB-45. We discuss the clinical and pathologic implications of this finding.

H Suzuki - One of the best experts on this subject based on the ideXlab platform.

  • Anti-melanoma monoclonal antibody HMB-45 on enhanced chemiluminescence-western blotting recognizes a 30-35 kDa melanosome-associated sialated glycoprotein.
    Melanoma research, 1996
    Co-Authors: A. M. Chiamenti, F. Vella, F. Bonetti, M. Pea, Sergio Ferrari, G Martignoni, A Benedetti, H Suzuki
    Abstract:

    HMB-45 is an anti-melanoma monoclonal antibody widely used in diagnostic pathology owing to its great specificity in identifying poorly differentiated melanomas. In this study, by a series of sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) immunoblots with the enhanced chemiluminescent (ECL) detection method on the HU-214 melanoma cell line, we identified the antigen of HMB-45 in a protein or proteins of 30-35 kDa. Although this result is in discrepancy with the previous literature which identified the antigen as a protein of 7 or 10 kDa, a family of proteins of 25-70 kDa of as a protein of 100 kDa (gp100), the present data indicate that the antigen signal we found might be specific. Furthermore, immunoblots on neuraminidase-treated cell lysates show, in agreement with already published data, that the antigen might be a sialated glycoprotein with the sialic acid involved in the epitope. Immunoblots on partially purified melanosomes confirmed the presence of the antigen in these organelles.